logo
Share SHARE
FONT-SIZE Plus   Neg

Repros Therapeutics To Meet With FDA To Discuss Phase 3 Study Design Of Androxal

Repros Therapeutics Inc.(RPRX) Monday said the FDA has scheduled a meeting in May to discuss the design of pivotal Phase 3 efficacy studies for Androxal, as well as the components of the overall drug development program required for NDA submission.

Androxal is an oral therapy intended for the treatment of secondary hypogonadism. Unlike the hormone replacement therapies currently approved to treat this disorder, Androxal restores testicular function resulting in normal synthesis of testosterone and continued spermatogenesis.

Repros said studies using approved testosterone replacement therapies as efficacy and safety comparators have shown the approved treatments result in suppression of important pituitary hormones that drive testicular function down to castration levels in a significant number of men.

Joseph Podolski, president and CEO of The Woodlands, Texas-based company, said," Our goal is to work with the FDA to provide a complete drug dossier for Androxal that exhibits the products' clinical benefit and safety. Depending on FDA comments, we believe we can submit the NDA early in 2014."

RPRX closed Monday's regular trade at $4.35, down $0.15 or 3.33%, on the Nasdaq. In the after-hours, the stock gained $0.01 or 0.23%. Over the past year, the stock traded in a range of $3.34 - $6.85.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Ryanair Holdings Plc pilots have rejected a cash bonus offered to them by the airline in exchange for cancelling their leave as the airline grapples with massive flight cancellations. Ryanair is cancelling 40 to 50 flights daily for the next six weeks, till the end of October, after it admitted to having "messed up" the planning of pilot holidays. Taco Bell, which records majority of its revenues from drive-thru windows, reportedly plans to open hundreds of new locations without a drive-thru by 2022, so it can finally sell more booze. The Tex-Mex brand plans to open 300 to 350 locations of new drive-thru-less cantinas by 2022 as it aims to make its presence known in urban areas, the reports said. Amazon.com may be talking with some middle-market pharmacy benefit managers or PBMs looking for various contractual arrangements, Axios reported, citing analysts at investment bank Leerink Partners. As per the report, the e-commerce giant, which recently entered the grocery industry with the purchase of Whole Foods for $13.4 billion, is eying to enter the pharmaceutical delivery business.
comments powered by Disqus
Follow RTT